AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$59.01
+$1.09 (+1.88%) 4:00 PM ET
After hours$59.15
+$0.14 (+0.24%) 4:32 AM ET
Prev closePrevC$57.92
OpenOpen$57.10
Day highHigh$59.04
Day lowLow$56.27
VolumeVol1,649,924
Avg volAvgVol2,632,649
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$9.23B
P/E ratio
115.71
FY Revenue
$1.22B
EPS
0.51
Gross Margin
65.22%
Sector
Healthcare
AI report sections
MIXED
TECH
Bio-Techne Corporation
Bio-Techne Corporation demonstrates strong short-term bullish momentum supported by multiple technical breakouts and high trading volume. However, recent and long-term price performance remains negative, and profitability metrics are modest relative to valuation. The stock’s forward-looking growth expectations and robust liquidity position provide some offset to elevated valuation risk. Institutional ownership is high, but the dividend yield is limited. Overall, the stock’s technical setup contrasts with its challenging historical returns and premium valuation.
AI summarized at 12:51 PM ET, 2025-10-01
Volume vs average
Intraday (cumulative)
−12% (Below avg)
Vol/Avg: 0.88×
RSI
39.54(Weak)
Weak (30–40)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.08 Signal: 0.07
Short-Term
-0.56 (Weak)
MACD: -2.15 Signal: -1.59
Long-Term
-0.80 (Weak)
MACD: -1.71 Signal: -0.91
Intraday trend score
54.00
LOW27.00HIGH56.00
Latest news
TECH•12 articles•Positive: 9Neutral: 3Negative: 0
PositiveBenzinga• Prnewswire
Bio-Techne Declares Dividend
Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.08 per share for the quarter ended December 31, 2025, payable on February 27, 2026, to shareholders of record on February 16, 2026. The company generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.
The company declared a dividend payment, demonstrating financial stability and profitability. The dividend announcement indicates confidence in cash flow generation and commitment to returning value to shareholders. Strong fiscal 2025 revenue of $1.2 billion+ supports the positive outlook.
Middle East Exosomes Market Research Report 2025-2033: Diagnostic and Therapeutic Adoption, R&D Investment, and Liquid Biopsy Demand Drive Growth
The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulatory requirements and high manufacturing costs.
Featured as a key market player in the exosomes sector, which is experiencing robust growth driven by diagnostics and therapeutics adoption.
PositiveBenzinga• Prnewswire
BIO-TECHNE DECLARES DIVIDEND
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on November 28, 2025, to shareholders of record on November 17, 2025. The global life sciences company generated over $1.2 billion in net sales in fiscal 2025.
Company reported strong financial performance with $1.2 billion in net sales, declared a consistent dividend, and highlighted its global presence in life sciences research and diagnostics
NeutralBenzinga• Globe Newswire
Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne
MDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.
MDXHTECHacquisitiondiagnosticsprostate testprecision medicine
Sentiment note
Company divested a business unit, likely to focus on core operations
PositiveBenzinga• Vandana Singh
Bio-Techne Stock Upgraded As Analyst Flags Attractive Entry Point
RBC Capital upgraded Bio-Techne to Outperform, raising price target from $61 to $73, citing potential for mid-single-digit revenue growth and attractive valuation after recent market selloff.
Analyst sees potential for revenue growth, valuation recovery, and strategic business focus after selling Exosome Diagnostics
PositiveGlobeNewswire Inc.• Towards Healthcare
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
The global recombinant human hair keratin protein market is experiencing rapid growth, driven by increasing demand in biomedical and cosmetic applications, with North America leading and Asia-Pacific showing the fastest growth potential by 2034.
Announced a strategic distribution agreement, suggesting market expansion and business development
NeutralThe Motley Fool• Jesterai
Bio-Techne (TECH) Q4 EPS Rises 8.2%
Bio-Techne reported Q4 fiscal 2025 earnings with modest revenue beat and non-GAAP EPS growth, but faced challenges including an $83.1 million impairment loss from divesting Exosome Diagnostics and margin pressures in its Diagnostics segment.
Mixed financial performance with revenue beat and EPS growth, offset by GAAP loss, segment margin compression, and strategic divestiture. Maintained focus on innovation and strategic investments despite market uncertainties.
NeutralBenzinga• Prnewswire
BIO-TECHNE DECLARES DIVIDEND
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on August 29, 2025, to shareholders of record as of August 18, 2025. The company is a global life sciences organization that generated approximately $1.2 billion in net sales in fiscal 2025.
The announcement is a standard corporate dividend declaration with no overtly positive or negative indicators. The company reports stable financial performance and provides routine financial guidance.
PositiveBenzinga• Prnewswire
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
Bio-Techne announced a quarterly dividend of $0.08 per share and a new $500 million share repurchase program, replacing the previous program.
TECHdividendshare repurchaseBio-Techne
Sentiment note
The company is returning capital to shareholders through a dividend and a new share repurchase program, which indicates confidence in the business and a commitment to creating shareholder value.
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.
The article mentions Asuragen Inc. by Bio-Techne Corporation as one of the leading companies in the MRD testing market, indicating their importance in the industry.
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - Global Forecast to 2030
The global complement C4 antibody market is expected to grow significantly due to the increasing prevalence of autoimmune diseases, advancements in biotechnology, and the rising focus on precision medicine and targeted therapies. The market is also driven by increased investment in immunotherapies and biologic drugs.
The company is mentioned as a key player in the complement C4 antibody market, indicating its involvement and potential growth opportunities in this market.
PositiveBenzinga• Prnewswire
Bio-Techne Declares Dividend
Bio-Techne Corporation announced that its Board of Directors has decided to pay a quarterly dividend of $0.08 per share. The dividend will be payable on February 28, 2025, to all common shareholders of record on February 17, 2025.
The company is declaring a quarterly dividend, which is generally seen as a positive sign for shareholders.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
